Graves Disease

Graves Disease

The Graves' disease market encompasses the diagnosis, treatment, and management of Graves' disease, an autoimmune disorder that leads to hyperthyroidism. Characterized by symptoms such as anxiety, rapid heartbeat, weight loss, and goiter, Graves' disease requires effective management to prevent serious complications. The market is driven by several growth factors, including the increasing prevalence of autoimmune disorders, advancements in diagnostic technologies, and the development of more effective treatment options, such as anti-thyroid medications, radioactive iodine therapy, and thyroid surgery. Additionally, rising awareness about thyroid disorders, an aging global population, and improved healthcare infrastructure further contribute to the expansion of the graves' disease market.

The market for graves disease is set to exhibit a growth rate of about 5%. This is mainly due to the technological advancements in diagnostic tools and techniques that are aiding in the early detection of graves' disease and rising investment in biopharmaceutical companies. For instance, in June 2022, Sling Therapeutics, Inc., a biopharmaceutical company launched a USD 35 million Series A financing led by TPG's The Rise Fund. The funds will support a Phase 2b clinical trial evaluating the company's investigational drug, linsitinib, for the treatment of thyroid eye disease (TED). TED predominantly affects women, and most frequently affects people with hyperthyroidism due to Graves' disease.

• Based on the treatment type, the market is divided into anti-thyroid medications, beta-blockers, radioactive iodine therapy, surgery (thyroidectomy), adjunctive therapies, and emerging treatments. Among them, the anti-thyroid medications category is expected to grow at a significant rate during the forecast period by offering a non-invasive and effective treatment option for managing hyperthyroidism, a key symptom of Graves' disease. These medications work by inhibiting the production of thyroid hormones, helping to restore hormone levels to normal and alleviate symptoms. Additionally, ongoing research and development efforts to improve the efficacy and safety of these medications contribute to the growth of this segment, further driving the graves disease market.
• Based on the end-user, the market is segmented into hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Homecare Settings. Among these, hospitals are significantly driving the growth of the graves disease market by serving as the primary point of care for diagnosis, treatment, and management. Hospitals provide access to specialized endocrinologists, advanced diagnostic tests, and treatments like thyroid surgery and radioactive iodine therapy. They also facilitate patient education and support programs, improving disease awareness and management. Hospitals' infrastructure and resources enable efficient care delivery, making them crucial for effective Graves' disease management worldwide.
• For a better understanding of the market adoption of graves disease, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America accounts for the major share during the forecast period. The region's advanced healthcare infrastructure facilitates early diagnosis and effective management of Graves' disease, contributing significantly to market expansion. High awareness levels among the population and healthcare professionals about autoimmune disorders ensure timely intervention, thereby increasing the demand for diagnostic and therapeutic solutions. Additionally, substantial investments in research and development by pharmaceutical companies and academic institutions are leading to the introduction of innovative treatments, such as biologics and advanced anti-thyroid medications, further propelling the market. Moreover, supportive government initiatives and favorable reimbursement policies enhance patient access to cutting-edge treatments, fostering market growth in North America.
• Some of the major players operating in the market include Merck & Co., Inc.; Abbott; Pfizer Inc.; GSK plc.; AbbVie Inc.; RLC Labs; Mylan N.V.; F. Hoffmann-La Roche Ltd; Medtronic; Ascendis Pharma.